Summary  
ECOG-ACRIN Cancer Research Group’s Marketing/Clinical Education and Awareness staff will use approved language/images to help increase awareness of EA2183 and support accrual efforts. The content below may be shared to the ECOG-ACRIN website, affiliated blogs, and social media channels. Links to these channels are included below. Staff at participating ECOG-ACRIN sites may also use this content on their own institutions’ marketing/communications channels.

ECOG-ACRIN Website  
<https://www.ecog-acrin.org>

ECOG-ACRIN Blogs  
<https://blog-ecog-acrin.org>  
<https://advocacy-ecog-acrin.org>

Social Media Channels  
Twitter: <https://twitter.com/eaonc>  
Facebook: <https://www.facebook.com/eaonc/>   
LinkedIn: <https://www.linkedin.com/company/ecog-acrin-cancer-research-group/>  
Instagram: <https://www.instagram.com/ecog_acrin/>  
YouTube (*video only*): <https://www.youtube.com/channel/UCAC_V1QdqlH2KdHOt7K2IHw>

Target Audience(s)  
The esophageal and gastric cancer community, including:

* Patients and survivors
* Caregivers
* Advocates
* Research, education, and advocacy organizations

Privacy/Confidentiality Considerations  
ECOG-ACRIN will make every possible effort to protect privacy and confidentiality by:

* Keeping social media post content general in nature and avoiding any specifics related to the trial or patients on the trial
* Refraining from direct engagement with individuals about their eligibility for trials
  + Instead, individuals will be directed to consult with their physician and/or the NCI’s Cancer Information Service
* Monitoring posts daily for inappropriate responses/interactions and flagging or removing as needed

General/Website Messaging

**EA2183 Study**

*Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients with Esophageal and Gastric Cancer that has Spread*

**Why consider participating in this study?**

* Research studies are an important way to test the effectiveness of new therapies and approaches for treating esophageal and gastric cancer.
* The usual treatment approach (the standard care most people get for oligometastatic esophageal and gastric adenocarcinoma) is treatment with Food and Drug Administration (FDA)-approved chemotherapy called **FOLFOX** (using the drugs leucovorin, 5-fluorouracil [5-FU], and oxaliplatin) or **CAPOX** (using the drugs capecitabine and oxaliplatin). More recently, an immunotherapy drug, nivolumab, has also been approved by the FDA in addition to chemotherapy, and it is now part of standard treatment.
* EA2183 aims to determine 1) if **adding radiotherapy** to the usual combination of drugs used to treat the kind of cancer you have will help you live longer, and 2) if this new approach is better or worse than the usual approach used to treat esophageal cancer or gastric adenocarcinoma.

**What does this study involve?**

* If you decide to take part in this study, you will receive standard treatment (i.e., FOLFOX or CAPOX, with or without nivolumab) as decided by your doctor, for about four months. Then you will be assigned by chance (randomized) to one of two groups:
  + **Group 1:** You will receive radiation therapy and continue your prior standard treatment for up to 2 years.
  + **Group 2:** You will receive radiation therapy and continue your prior standard treatment for up to 2 years.
* Each patient has a 2/3 chance of being in Group 1 and a 1/3 chance of being in Group 2.

You agree to take part in the study and sign the consent form

**Group 1**  
Radiation therapy followed by standard therapy

Randomize-the computer will randomly put you in a study group\*

Standard treatment for 4 months



**Group 2**  
Continue standard therapy

\*Patients are also able to register to EA2183 at the randomization step, after they have started first-line standard treatment. They would enroll after completion of 4 months of treatment, if their tumors have not progressed.

* After you finish your study treatment, your doctor will continue to see you every 3 months for the first 2 years. Then, you will be seen every 6 months for up to 5 years. These post-study visits are routine clinic visits that patients with metastatic esophageal and gastric adenocarcinoma usually have.

**Who will take part in this study?**

* Approximately 314 people diagnosed with esophageal or gastric cancer that has spread will begin this study, and then study participants whose cancer is not growing will continue and will be assigned to Group 1 or Group 2.
* You can decide to stop taking part in the study at any time, even after you have enrolled.

**What are the costs of taking part in this study?**

* Just as you would if you were getting the usual care for your cancer, you and/or your insurance plan will need to pay for some or all of the costs of medical care you get as part of this study. Check with your insurance company to find out what they will pay for.

**If you would like to know more**

About the EA2183 study, talk with your doctor, or:

* Visit www.ecog-acrin.org and search EA2183, then select the link to the EA2183 Home Page.
  + If you are seeking information about the locations where the study is available, scroll down the page to Locations and Contacts and click the + sign.
* Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237)

About clinical trials:

* General cancer information: visit the NCI website at [www.cancer.gov](http://www.cancer.gov)
* Insurance coverage: visit www.cancer.gov/clinicaltrials/learningabout/payingfor

About ECOG-ACRIN:


* Visit [www.ecog-acrin.org](http://www.ecog-acrin.org)
* For a list of patient resources and links to patient advocacy groups, visit <https://ecog-acrin.org/patients/resources>

Social Media Messaging

|  |  |
| --- | --- |
| **Facebook/LinkedIn** | **Twitter** |
| Clinical trial EA2183, led by Dr. Nataliya V. Uboha of @UWHealth, is testing the addition of radiotherapy to chemotherapy for patients with esophageal and gastric cancer. For more information: https://bit.ly/ea2183 | #ClinicalTrial EA2183, led by @NataliyaUboha of @UWHealth, is testing the addition of #radiotherapy to chemotherapy for patients w/ #esophageal and #GastricCancer. For more: https://bit.ly/ea2183 #StomachCancer #GICSM #esocsm |
| Do you have esophageal or gastric cancer that has spread to a number of places in your body? If the cancer has spread to 1–3 places, you may be able to participate in clinical trial EA2183. For more info: https://bit.ly/ea2183 | Do you have #esophageal or #GastricCancer that has spread to a number of places in your body? If the #cancer has spread to 1–3 places, you may be able to participate in #clinicaltrial EA2183. For more info: <https://bit.ly/ea2183> |
| You may be eligible to participate in a clinical study that is testing the addition of radiotherapy to chemotherapy for patients with esophageal cancer and stomach cancer. Learn more: https://bit.ly/ea2183 | You may be eligible to participate in a clinical study that is testing the addition of #radiotherapy to #chemotherapy for patients with #EsophagealCancer and #StomachCancer. Learn more: <https://bit.ly/ea2183> #esocsm #gicsm |

**Hashtags:** #ClinicalTrial #radiotherapy #GastricCancer #esophageal #EsophagealCancer #esocsm #StomachCancer #GICSM

Images



Graphical user interface, text, application

Description automatically generated